Evolus (EOLS) Competitors $9.87 +0.22 (+2.28%) Closing price 04:00 PM EasternExtended Trading$10.07 +0.21 (+2.08%) As of 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock EOLS vs. LYEL, APLS, OGN, HCM, IBRX, AMRX, XENE, MIRM, ARWR, and AAPGShould you be buying Evolus stock or one of its competitors? The main competitors of Evolus include Lyell Immunopharma (LYEL), Apellis Pharmaceuticals (APLS), Organon & Co. (OGN), HUTCHMED (HCM), ImmunityBio (IBRX), Amneal Pharmaceuticals (AMRX), Xenon Pharmaceuticals (XENE), Mirum Pharmaceuticals (MIRM), Arrowhead Pharmaceuticals (ARWR), and Ascentage Pharma Group International (AAPG). These companies are all part of the "pharmaceutical products" industry. Evolus vs. Lyell Immunopharma Apellis Pharmaceuticals Organon & Co. HUTCHMED ImmunityBio Amneal Pharmaceuticals Xenon Pharmaceuticals Mirum Pharmaceuticals Arrowhead Pharmaceuticals Ascentage Pharma Group International Lyell Immunopharma (NASDAQ:LYEL) and Evolus (NASDAQ:EOLS) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their valuation, media sentiment, analyst recommendations, community ranking, earnings, risk, institutional ownership, profitability and dividends. Does the media prefer LYEL or EOLS? In the previous week, Evolus had 1 more articles in the media than Lyell Immunopharma. MarketBeat recorded 7 mentions for Evolus and 6 mentions for Lyell Immunopharma. Evolus' average media sentiment score of 0.79 beat Lyell Immunopharma's score of -0.25 indicating that Evolus is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Lyell Immunopharma 0 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Evolus 3 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Does the MarketBeat Community believe in LYEL or EOLS? Evolus received 349 more outperform votes than Lyell Immunopharma when rated by MarketBeat users. Likewise, 73.19% of users gave Evolus an outperform vote while only 43.75% of users gave Lyell Immunopharma an outperform vote. CompanyUnderperformOutperformLyell ImmunopharmaOutperform Votes1443.75% Underperform Votes1856.25% EvolusOutperform Votes36373.19% Underperform Votes13326.81% Do analysts rate LYEL or EOLS? Lyell Immunopharma presently has a consensus price target of $20.00, indicating a potential upside of 85.19%. Evolus has a consensus price target of $23.75, indicating a potential upside of 140.63%. Given Evolus' stronger consensus rating and higher probable upside, analysts plainly believe Evolus is more favorable than Lyell Immunopharma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Lyell Immunopharma 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50Evolus 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 3.00 Do institutionals & insiders believe in LYEL or EOLS? 66.1% of Lyell Immunopharma shares are owned by institutional investors. Comparatively, 90.7% of Evolus shares are owned by institutional investors. 25.1% of Lyell Immunopharma shares are owned by company insiders. Comparatively, 5.9% of Evolus shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth. Which has more risk and volatility, LYEL or EOLS? Lyell Immunopharma has a beta of -0.26, indicating that its stock price is 126% less volatile than the S&P 500. Comparatively, Evolus has a beta of 1, indicating that its stock price has a similar volatility profile to the S&P 500. Is LYEL or EOLS more profitable? Evolus has a net margin of -22.33% compared to Lyell Immunopharma's net margin of -323,792.09%. Lyell Immunopharma's return on equity of -34.64% beat Evolus' return on equity.Company Net Margins Return on Equity Return on Assets Lyell Immunopharma-323,792.09% -34.64% -30.02% Evolus -22.33%-847.60%-22.15% Which has preferable valuation and earnings, LYEL or EOLS? Evolus has higher revenue and earnings than Lyell Immunopharma. Evolus is trading at a lower price-to-earnings ratio than Lyell Immunopharma, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioLyell Immunopharma$65K2,460.41-$234.63M-$25.00-0.43Evolus$275.46M2.31-$61.69M-$0.89-11.09 SummaryEvolus beats Lyell Immunopharma on 15 of the 18 factors compared between the two stocks. Get Evolus News Delivered to You Automatically Sign up to receive the latest news and ratings for EOLS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart EOLS vs. The Competition Export to ExcelMetricEvolusPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$636.38M$6.83B$5.57B$8.67BDividend YieldN/A2.50%5.27%4.19%P/E Ratio-10.858.7927.2020.17Price / Sales2.31263.51412.92161.90Price / CashN/A65.8538.2534.64Price / Book-27.426.677.114.72Net Income-$61.69M$143.49M$3.23B$247.80M7 Day Performance-0.90%6.34%4.61%3.36%1 Month Performance0.71%15.43%13.35%9.71%1 Year Performance-13.65%6.87%31.75%14.41% Evolus Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)EOLSEvolus3.8905 of 5 stars$9.87+2.3%$23.75+140.6%-17.5%$636.38M$275.46M-10.85170Insider TradeLYELLyell Immunopharma1.9897 of 5 stars$8.22-5.9%$1.00-87.8%-74.3%$2.43B$65,000.00-10.40270News CoverageHigh Trading VolumeAPLSApellis Pharmaceuticals4.6354 of 5 stars$19.14+13.1%$40.05+109.3%-52.0%$2.41B$775.84M-9.43770Analyst RevisionHigh Trading VolumeOGNOrganon & Co.4.9249 of 5 stars$9.22-0.1%$18.00+95.3%-53.0%$2.40B$6.29B2.7710,000Trending NewsHCMHUTCHMED1.4425 of 5 stars$13.60-2.1%$19.00+39.7%-10.1%$2.37B$630.20M0.001,760IBRXImmunityBio2.0211 of 5 stars$2.67+0.4%$12.25+358.8%-43.6%$2.36B$31.22M-2.90590High Trading VolumeAMRXAmneal Pharmaceuticals3.7025 of 5 stars$7.42+1.4%$11.50+55.0%+12.7%$2.33B$2.83B-10.917,600XENEXenon Pharmaceuticals3.4248 of 5 stars$30.07+4.2%$54.82+82.3%-16.5%$2.31B$7.50M-10.66210Analyst RevisionMIRMMirum Pharmaceuticals3.0147 of 5 stars$45.97+3.4%$60.73+32.1%+87.7%$2.28B$379.25M-22.76140Positive NewsARWRArrowhead Pharmaceuticals3.5595 of 5 stars$16.40+2.1%$42.13+156.9%-30.7%$2.26B$545.21M-3.17400AAPGAscentage Pharma Group InternationalN/A$25.22+3.4%N/AN/A$2.20B$980.65M0.00600News Coverage Related Companies and Tools Related Companies Lyell Immunopharma Competitors Apellis Pharmaceuticals Competitors Organon & Co. Competitors HUTCHMED Competitors ImmunityBio Competitors Amneal Pharmaceuticals Competitors Xenon Pharmaceuticals Competitors Mirum Pharmaceuticals Competitors Arrowhead Pharmaceuticals Competitors Ascentage Pharma Group International Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:EOLS) was last updated on 6/10/2025 by MarketBeat.com Staff From Our PartnersBanks aren’t ready for this altcoin—are you?While everyone's distracted by Bitcoin's moves, a stealth revolution is underway. One altcoin is quietly po...Crypto 101 Media | SponsoredTrump Nominates “Next Elon”Elon's Replacement? You've been told Elon Musk has been forced out of DC. But did you know his successor ha...Altimetry | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredGet Ready for Elon Musk’s BIGGEST Comeback YetTesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… ...Brownstone Research | SponsoredNew Rule Hits in July — The Smart Money Already MovedA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...American Alternative | SponsoredBig Changes Coming to Social Security?According to legendary investor Louis Navellier... This new Trump move could soon not only save Social Secu...InvestorPlace | SponsoredSHOCKING: Musk's Pentagon Secret Mission...It's about a harrowing message discovered on December 16, 2024: "美国军方暗杀名单" It's the reason President Tru...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Evolus, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Evolus With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy EOLS Stock Free EOLS Stock Alerts